International Journal of Radiation Oncology*Biology*Physics
Clinical InvestigationThe Impact of Radiation Therapy on the Risk of Lymphedema After Treatment for Breast Cancer: A Prospective Cohort Study
Introduction
Women treated for breast cancer have increasingly successful outcomes; therefore, late toxicities of treatment are assuming greater importance. Lymphedema causes significant physical and psychosocial side effects and is of concern for women undergoing breast cancer therapy 1, 2, 3, 4. Data regarding the risk of lymphedema with the inclusion of adjuvant radiation therapy are limited and are often based on retrospective cohorts, varying definitions of lymphedema, and heterogeneous patient populations.
Of particular interest is the risk of lymphedema with extended radiation therapy fields. Regional lymph node radiation (RLNR) is routinely used in patients with ≥4 positive lymph nodes (LNs) found at the time of lumpectomy or mastectomy with axillary LN dissection (ALND) (5). These clinical practices are based on trials that demonstrated decreased rates of locoregional failure, increased disease-free survival (DFS), and increased overall survival (OS) for high-risk or LN-positive patients with the receipt of postmastectomy radiation therapy 6, 7. Inasmch as women undergoing RLNR most often also undergo sentinel LN biopsy (SLNB) or ALND, which have a reported incidence of lymphedema up to 11% and 30%, respectively 8, 9, 10, quantifying the additional risk with inclusion of RLNR has significant clinical implications.
In this study, we used a large cohort of breast cancer patients prospectively screened for lymphedema and analyzed arm volume changes to quantify the risk of lymphedema with inclusion of adjuvant radiation therapy. The types of radiation therapy analyzed included receipt of no radiation, partial breast irradiation (PBI), whole breast irradiation (WBI) or chest wall radiation alone, or WBI/chest wall radiation with RLNR. Among patients who received RLNR, we sought to determine whether the addition of a posterior axillary boost (PAB) to supraclavicular irradiation (SC) increased the risk of lymphedema compared with SC alone.
Section snippets
Patients
We included 1476 women who underwent surgery for unilateral or bilateral breast cancer from 2005 to 2012. Patients were recruited at the time of initial consultation in a multidisciplinary clinic, and all underwent surgery at our institution. All patients, regardless of T or N stage, were included except for patients with pre-existing lymphedema. Treating each breast individually, we had 1501 unique cases. Each patient had >3 months of postsurgical follow-up.
Lymphedema definition and measurement
According to the standard of care at
Results
Of the 1476 patients, 1262 (86%) underwent unilateral breast surgery and 214 (14%) underwent bilateral breast surgery for unilateral (n=189) or bilateral (n=25) breast cancer. Postoperative radiation therapy was given after 1099 of 1501 (73%) individual breast surgeries. The clinical and pathologic characteristics are given in Table 2. The median postoperative follow-up time was 25.4 months (range, 3.0-82.6 months), with a median of 4 postoperative measurements per patient (range, 1-25
Discussion
The current study used a cohort of 1476 breast cancer patients prospectively screened for lymphedema at a single institution. The patients in our study were treated for breast cancer between 2005 and 2012, and they thereby represent a population treated with modern radiation therapy and surgical techniques over a relatively short time. The risk factors for lymphedema, including adjuvant radiation therapy, have been previously evaluated; however, most studies have used retrospectively collected
Acknowledgment
The authors thank Nadine R. Taghian, whose continuous dedication helped expedite completion of this project, and whose efforts are greatly appreciated.
References (34)
- et al.
Factors associated with long-term functional outcomes and psychological sequelae in women after breast cancer
Breast
(2012) - et al.
Radiotherapy for invasive breast cancer in North America and Europe: Results of a survey
Int J Radiat Oncol Biol Phys
(2005) - et al.
Standardized method for quantification of developing lymphedema in patients treated for breast cancer
Int J Radiat Oncol Biol Phys
(2011) - et al.
Variability of target and normal structure delineation for breast cancer radiotherapy: An RTOG multi-institutional and multiobserver study
Int J Radiat Oncol Biol Phys
(2009) - et al.
External beam accelerated partial-breast irradiation using 32 gy in 8 twice-daily fractions: 5-year results of a prospective study
Int J Radiat Oncol Biol Phys
(2012) - et al.
Accelerated partial breast irradiation using proton beams: Initial dosimetric experience
Int J Radiat Oncol Biol Phys
(2006) - et al.
Does axillary boost increase lymphedema compared with supraclavicular radiation alone after breast conservation?
Int J Radiat Oncol Biol Phys
(2008) - et al.
Factors associated with the development of breast cancer-related lymphedema after whole-breast irradiation
Int J Radiat Oncol Biol Phys
(2012) - et al.
Arm morbidity after sector resection and axillary dissection with or without postoperative radiotherapy in breast cancer stage I. Results from a randomised trial. Uppsala-Orebro Breast Cancer Study Group
Eur J Cancer
(1997) - et al.
Incidence of unilateral arm lymphoedema after breast cancer: A systematic review and meta-analysis
Lancet Oncol
(2013)
Infrared optoelectronic volumetry: The ideal way to measure limb volume
Eur J Vasc Endovasc Surg
Risk factors for lymphedema in breast cancer survivors: The Iowa Women's Health Study
Breast Cancer Res Treat
Quality-of-life and body image impairments in patients with lymphedema
Lymphology
The psychological morbidity of breast cancer-related arm swelling: Psychological morbidity of lymphoedema
Cancer
Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial
N Engl J Med
Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial
J Natl Cancer Inst
Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: Objective measurements
J Clin Oncol
Cited by (198)
Managing the Morbidity: Individualizing Risk Assessment, Diagnosis, and Treatment Options for Upper Extremity Lymphedema
2023, Surgical Oncology Clinics of North AmericaRadiation Treatment for Breast Cancer
2023, Surgical Clinics of North AmericaThe prevalence of arm lymphedema after radiation treatment in patients with breast cancer
2023, Journal of Radiotherapy in PracticeLymphatic Microsurgical Preventative Healing Approach for the Primary Prevention of Lymphedema: A 4-Year Follow-Up
2024, Plastic and Reconstructive Surgery
Supported by Award # RO1CA139118 (A. Taghian) and Award # P50CA0893932 (A. Taghian) from the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the views of the National Cancer Institute or the National Institutes of Health.
Conflict of interest: none.